- Home
- BUI vs CSTL Comparison
BUI vs CSTL Comparison
Compare BUI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUI
- CSTL
- Stock Information
- Founded
- BUI 2011
- CSTL 2007
- Country
- BUI United States
- CSTL United States
- Employees
- BUI N/A
- CSTL N/A
- Industry
- BUI Trusts Except Educational Religious and Charitable
- CSTL Medical Specialities
- Sector
- BUI Finance
- CSTL Health Care
- Exchange
- BUI Nasdaq
- CSTL Nasdaq
- Market Cap
- BUI 589.4M
- CSTL 661.7M
- IPO Year
- BUI N/A
- CSTL 2019
- Fundamental
- Price
- BUI $25.94
- CSTL $33.61
- Analyst Decision
- BUI
- CSTL Strong Buy
- Analyst Count
- BUI 0
- CSTL 6
- Target Price
- BUI N/A
- CSTL $38.67
- AVG Volume (30 Days)
- BUI 59.8K
- CSTL 397.7K
- Earning Date
- BUI 01-01-0001
- CSTL 11-03-2025
- Dividend Yield
- BUI 6.79%
- CSTL N/A
- EPS Growth
- BUI N/A
- CSTL N/A
- EPS
- BUI 2.75
- CSTL N/A
- Revenue
- BUI N/A
- CSTL $343,530,000.00
- Revenue This Year
- BUI N/A
- CSTL N/A
- Revenue Next Year
- BUI N/A
- CSTL N/A
- P/E Ratio
- BUI $7.77
- CSTL N/A
- Revenue Growth
- BUI N/A
- CSTL 10.15
- 52 Week Low
- BUI $18.73
- CSTL $14.59
- 52 Week High
- BUI $24.22
- CSTL $34.64
- Technical
- Relative Strength Index (RSI)
- BUI 37.28
- CSTL 85.29
- Support Level
- BUI $26.31
- CSTL $23.31
- Resistance Level
- BUI $26.78
- CSTL $34.36
- Average True Range (ATR)
- BUI 0.30
- CSTL 1.47
- MACD
- BUI -0.07
- CSTL 1.09
- Stochastic Oscillator
- BUI 1.11
- CSTL 94.80
About BUI BlackRock Utility Infrastructure & Power Opportunities Trust
BlackRock Utility Infrastructure & Power Opportunities Trust is a closed-end management investment company. Its investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing of writing (selling) call and put options.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.